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A detailed understanding of host-pathogen interactions provides exciting opportunities
to interfere with the infection process. Anti-virulence compounds aim to modulate or
pacify pathogenesis by reducing expression of critical virulence determinants. In particular,
prevention of attachment by inhibiting adhesion mechanisms has been the subject of
intense research. Whilst it has proven relatively straightforward to develop robust screens
for potential anti-virulence compounds, understanding their precise mode of action has
proven much more challenging. In this review we illustrate this challenge from our own
experiences working with the salicylidene acylhydrazide group of compounds. We aim to
provide a useful perspective to guide researchers interested in this field and to avoid some
of the obvious pitfalls.
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INTRODUCTION
The treatment of bacterial infections has become more challeng-
ing due to the increased prevalence of antibiotic-resistant strains
and a stark reduction in the development of novel anti-bacterials.
The current armory of compounds inhibit enzymes that are often
essential to the survival of the pathogen, for example β-lactams
and aminoglycosides that target bacterial cell wall biosynthesis
and translation respectively. As these processes are essential for
growth, the selective pressure imposed by antibiotics is strong,
and the development of resistance mechanisms high. The iden-
tification of novel targets that are not essential for survival per se
is therefore becoming an active area of research.
The AV approach is one that specifically targets “virulence fac-
tors” used by pathogens to facilitate the infection process. The
application of AV compounds against factors such as quorum
sensing, adhesins, and secretion systems has been tested, however
the development of these compounds is still in the early stages.
Whether targeting virulence factors will lead to lower selective
pressure for the generation of resistance is an interesting question
and has been scrutinized recently (Allen et al., 2014). Certainly
anti-virulence (AV) approaches can have merit, for example when
the use of traditional antibiotics is not appropriate. The clinical
symptoms associated with Enterohaemorrhagic Escherichia coli
(EHEC) infections have been shown to increase in severity fol-
lowing administration of certain antibiotics. This is a result of
the release of Shiga-toxin following bacterial lysis (Zhang et al.,
2000).
The focus of this review is the development of AV com-
pounds that inhibit the Type Three Secretion System (T3SS), a
virulence factor important for the pathogenicity of several Gram-
negative pathogens, including Salmonella spp., Yersinia spp. and
pathogenic E. coli. Here we will describe the different approaches
used to identify AV compounds, along with their respective tar-
gets, and the various methods of target validation, with particular
emphasis on the experience we have gained from working on a
class of T3SS inhibitors, the salicylidene acylhydrazides.
THE TYPE THREE SECRETION SYSTEM
The T3SS is a key virulence determinant for a diverse range
of Gram-negative pathogens. Species as distinct as Yersinia and
Erwinia use the T3SS to secrete and inject pathogenicity pro-
teins into the cytosol of eukaryotic host cell (Hueck, 1998).Whilst
the core apparatus proteins of the T3SS are relatively conserved,
the functions of the secreted effector proteins are highly species-
specific. EHEC and enteropathogenic E. coli (EPEC) induce gross
reorganization of the actin cytoskeleton of host-epithelial cells
leading to the formation of attaching and effacing (A/E) lesions
that act as “pedestals” allowing intimate attachment of the bacte-
ria to the host. Attachment is largely achieved by the translocation
of effector proteins such as Tir (the translocated initimin recep-
tor). In both EHEC and EPEC, the entire T3SS is chromosomally
encoded by a pathogenicity island called the locus of enterocyte
effacement (LEE) (McDaniel et al., 1995). This T3SS is geneti-
cally quite distinct from that of Yersinia species, the “Ysc-Yop”
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system, which is plasmid encoded and regulated by different
environmental signals (Lindler, 2004).
THE SEARCH FOR T3SS INHIBITORS
Deletion of the T3SS has a profound effect on the virulence
potential of Gram-negative pathogens in vivo, making its inhi-
bition an attractive prospect. Initial screens for a T3SS inhibitor
made use of a high throughput (HTP) approach that tested large
chemical libraries, consisting of both synthetic and natural com-
pounds, against whole bacteria (Linington et al., 2002; Kauppi
et al., 2003; Nordfelth et al., 2005). The use of a bacterial screening
model overcomes several problems associated with drug discov-
ery, for example cell-permeability or drug-efflux. Several of these
screens employ the use of a transcriptional-reporter assay, which
couples the expression of virulence genes into a fluorescent or
luminescent read-out that can be easily quantified in a HTP
manner.
The first reported chemical inhibitor of the T3SS was identi-
fied in 2002 by Linington et al. who screened chemical extracts
from the marine sponge Caminus sphaeroconia against EPEC
(Linington et al., 2002). The screen looked for compounds that
decreased the secretion of EspB, a T3SS protein, and displayed no
antibacterial activity. The product caminoside (Table 1; depicts
key compounds described in this review) was found to have these
properties with an IC50 of 5.1μg/ml. Despite the promise of this
caminoside, its cellular targets were not identified due to the
difficulty of synthesizing this natural compound (Zhang et al.,
2010).
Several other natural products have been shown to decrease
the expression of the T3SS. Aurodox, produced by Streptomyces
goldiniensis, was recently shown to inhibit EPEC T3SS mediated
hemolysis in vitro, with an IC50 of 1.8μM (Kimura et al., 2011).
Aurodox was also shown to be effective in vivo when tested in
a mouse model of infection using the natural mouse pathogen
Citrobacter rodentium, where mice treated with Aurodox survived
a lethal bacterial load (Kimura et al., 2011). Treatment of Gram-
negative species with Aurodox resulted in a specific decrease in
expression of the T3SS suggesting that it may be interacting with
a T3SS transcriptional regulator. Another class of compounds
produced by a Streptomyces species (K01-0509) are the guadi-
nomines, which were shown to inhibit T3SS in EPEC in vitrowith
IC50 values of lower than 0.01μg/ml (Iwatsuki et al., 2008). Since
the guadinomines appear to be highly potent with no antibac-
terial activity they are attractive lead compounds, however their
efficacy in vivo has yet to be confirmed.
One of the most extensively studied group of AV compounds
are the salicylidene acylhydrazides (SA), a class of inhibitors that
were identified from a chemical screen of 9400 compounds car-
ried out by Kauppi et al. at the University of Umeå (Kauppi
et al., 2003). The screen was performed on Y. pseudotuberculo-
sis expressing a yopE-luciferase transcriptional fusion, where the
yopE promoter was fused to the luxAB cassette. YopE is a secreted
effector protein; therefore a decrease in luciferase activity from
the yopE promoter was correlated to reduced expression of the
T3SS. This assay provided a rapid system to monitor processes
regulating secretion-specific transcription. However, like all tran-
scriptional reporters, it is rather indirect and does not provide
data on whether the T3SS is functional and secreting effectors.
Compounds that showed no antibacterial activity were character-
ized further, leaving four lead compounds from the initial screen.
These were all demonstrated to decrease the secretion of effector
proteins (YopE, YopD and YopH) in a dose dependent manner
with an IC50 of less than 50μM. Owing to the structural sim-
ilarity between the Ysc T3SS apparatus and the flagellum, the
compounds were tested for inhibition of motility. Only one of the
four compounds, INP0010/ME0052, was shown to have an effect
on motility, which was interpreted by some groups to indicate
that the compounds are binding to a related structural compo-
nent or to a common regulator of these systems (Kauppi et al.,
2003).
Several groups later tested the SA compounds on a range of
Gram-negative pathogens. The obligate intracellular pathogen
Chlamydia trachomatis was shown to be affected by an SA com-
pound (INP0400), identified in the original screen by Kauppi
et al. (2003; Muschiol et al., 2006; Wolf et al., 2006). Treatment
with this compound disrupted the normal infection cycle and
prevented differentiation and multiplication in mammalian cells
(Muschiol et al., 2006; Wolf et al., 2006). At the time of this
study relatively little was known about the role played by the
T3SS in this pathogen, thus the use of these compounds revealed
insights into the importance of the T3SS in the switch between
the metabolically inert “elementary body” and the infective vege-
tative state of the pathogen. At the time, there were only limited
genetic tools available for Chlamydia therefore INP0400 permit-
ted inhibition of T3SS expression throughout the developmental
cycle of this pathogen (Wolf et al., 2006).
Subsequent work showed that Salmonella enterica serovar
Typhimurium was also susceptible to the SA compounds. Dose
dependent inhibition of SPI-1, one of the two T3SSs encoded in
Salmonella (Hudson et al., 2007) was demonstrated. The com-
pounds (e.g., INP0031/ME0055) had no effect on the growth
of the pathogen in vitro and reduced SPI-1 mediated invasion
of HeLa cells by up to 60%. The study also showed that pre-
incubation of the bacteria with the compounds reduced the level
of inflammation in an in vivo bovine intestinal ligated loop
model. These data indicated that the compounds reduced the
virulence of Salmonella in vivo (Hudson et al., 2007). Further
studies in Salmonella by Negrea et al. confirmed the ability of the
SA compound (INP0400) to inhibit SPI-1 activity (Negrea et al.,
2007). They also demonstrated the compounds to be effective
inhibitors of SPI-2 mediated secretion, and that treatment with
the compounds reduced intracellular replication. Two of the nine
compounds tested were shown to significantly reduce the motility
of Salmonella in soft agar (Negrea et al., 2007).
Veenendaal et al. found that the SA compounds INP0402
and INP0400 were the most effective at reducing T3SS in
Shigella flexneri, an invasive intracellular Gram-negative pathogen
(Veenendaal et al., 2009). Treatment with the compound
reduced its ability to invade HeLa cells and its ability to
induce macrophage apoptosis, both indicative of T3SS inhibition
(Veenendaal et al., 2009).
The activity of the SA compounds against EHEC was shown
by our group to be effective at decreasing LEE T3S in a dose
dependentmanner (Tree et al., 2009). This study showed INP0031
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Table 1 | Anti-virulence compounds discussed in this review.
Compound Structure Source Phenotype
tested
Effective
against
IC50 References
Caminoside Marine sponge
(Caminus
sphaeroconia)
Effector protein
secretion (EspB)
EPEC 5.1μg ml−1 Linington et al.,
2002
Aurodox Streptomyces
sp. extract
Effector protein
secretion (EspB)
T3SS- mediated
haemolysis
EPEC
C. rodentium
1.8μM Kimura et al.,
2011
Guadinomines Streptomyces
sp. extract
T3SS induced
haemolysis
EPEC <0.01μg
ml−1
Iwatsuki et al.,
2008
INP0010 /
ME0052
Synthetic
compound
library
(ChemBridge)
Effector protein
secretion (Yop,
EspB)
Yersinia
Salmonella
EHEC
25μM Nordfelth et al.,
2005
INP0031 /
ME0055
Synthetic
compound
library
(ChemBridge)
Effector protein
secretion (EspB,
Tir)
EHEC 25μM Hudson et al.,
2007
INP0341 Synthetic
compound
library
(ChemBridge)
Intracellular
invasion assay
Chlamydia <50μM Slepenkin et al.,
2007
INP0400 Synthetic
compound
library
(ChemBridge)
Effector protein
secretion (Yop,
EspB),
Intracellular
invasion assay
Yersinia
Chlamydia
Salmonella
Shigella
25μM Muschiol et al.,
2006; Negrea
et al., 2007;
Slepenkin et al.,
2007;
Veenendaal
et al., 2009
INP0402 Synthetic
compound
library
(ChemBridge)
Intracellular
invasion assay
Shigella Veenendaal
et al., 2009
INP0403 /
ME0053
Synthetic
compound
library
(ChemBridge)
Effector protein
secretion (EspB),
SpI1 expression
Salmonella
EHEC
25μM Tree et al., 2009;
Layton et al.,
2010; Wang
et al., 2011
INP0406 Synthetic
compound
library
(ChemBridge)
Intracellular
invasion assay
Chlamydia Slepenkin et al.,
2007
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to be the most effective compound at inhibiting LEE T3S and
A/E lesion formation. All of the compounds tested (INP0010,
INP0103, INP0401 and INP0031) increased the production of
flagella (Tree et al., 2009). The observation that the SA com-
pounds decreased expression of the T3SS but increased flagella
expression indicated that the mechanism of action might be
through a regulatory mechanism.
In summary, the SA compounds have been shown to be
effective inhibitors of T3S in several species of Gram-negative
pathogens. In all studies the authors observed no antibacterial
activity, which is key as AV compounds should not decrease the
survival of the pathogen. Several studies showed that in addi-
tion to affecting the T3SS, the expression of motility genes was
also affected, however the effects between species were not consis-
tent. Although it is known that the compounds inhibit the T3SS,
the precise mechanisms underlying their mechanism of action
(MOA) is yet to be elucidated.
PROPOSED MECHANISM OF ACTION OF THE SA
COMPOUNDS
There are three main schools of thought about how the SA
compounds function. Firstly, by disrupting cellular iron stores.
Secondly, by directly interacting with a component of the T3SS
apparatus, and thirdly, by causing dis-regulation of T3SS expres-
sion. The finding that the activity of the compounds could be
reversed following the addition of iron to the cell culture media
was first reported by Slepenkin et al. (2007). This study showed
that the addition of iron to HeLa cells infected with C. tra-
chomatis reversed the effects of the inhibitors. This effect was
not seen when other divalent metal ions were added. However,
these results were somewhat inconclusive since INP compounds
that did not affect the T3SS in Chlamydia (INP0406) chelated
iron to the same extent as INP0341, a potent inhibitor (Slepenkin
et al., 2007). Indeed, the most promising clinical application of
the SA compounds is for protection against Chlamydia. For this
strict intracellular pathogen the SA compounds affect not only
the T3SS but also growth and replication of the bacteria, almost
invariably through iron sequestration (Ur-Rehman et al., 2012).
When used as a vaginal biocide, SA compounds were able to sig-
nificantly protect mice from a vaginal infection of C. trachomatis
(Slepenkin et al., 2011). A similar study by Layton et al. indicated
that the effect of the SA compounds could be partially reversed by
the addition of iron (Layton et al., 2010). Transcriptomic anal-
ysis of Salmonella treated with INP0403 showed a significant
increase in several genes involved in iron regulation (Layton et al.,
2010). However, the addition of iron did not fully reverse the
anti-SPI1 T3SS activity of INP0403. Microarray studies carried
out on EHEC grown in the presence of iron found that SA com-
pounds (INP0010 and INP0031) lead to a significant decrease in
the expression of the LEE (Tree et al., 2009), thus indicating that
in this case iron is not inhibiting the action of the SA compounds.
Therefore, it remains unclear how iron affects the activity of the
SA compounds and further work is required to clarify the effects
of iron on the T3SS.
Veenendaal et al. proposed that the compounds were acting
directly on a component of the T3SS. The reports of motility
also being affected by the compounds led to the conclusion that
the component being targeted may be one that is homologous
between the T3SS and flagellar systems (Veenendaal et al., 2009).
The evidence for this proposed mechanism was that following SA
compound treatment of Shigella, the needle filaments of the T3SS
were significantly shorter than for untreated cells indicating that
the compounds were affecting needle assembly (Veenendaal et al.,
2009). A further study by the same group sought to determine
this common component in Salmonella. By using strains deficient
in three soluble components of the flagella apparatus they aimed
to identify which of these were responsible for the change in
motility seen following compound treatment (Martinez-Argudo
et al., 2013). However, this study was unable to show that the SA
compounds directly affected flagellar components. The authors
concluded that the SA compounds were not directly inhibiting
T3SS or flagellar components and were most likely interacting
with other targets within the cell and indirectly affecting the
expression of these virulence factors (Martinez-Argudo et al.,
2013).
Transcriptomic profiling of EHEC treated with 20μM
ME0052 or ME0055 resulted in the decreased expression of the
five operons that comprise the LEE as well as an increase in the
expression of flagellar associated genes (Tree et al., 2009). These
data provided important clues as to how the SA compounds
might be working. Firstly, the reduction in transcription of the
entire LEE suggested that the compounds either affected the mas-
ter regulator of the system (Ler) or an upstream regulator that
affected Ler itself. Indirect support for this hypothesis comes from
the observation that deletion mutants for LEE genes encoding
proteins of the secretion system itself do not result in regulatory
feedback and a reduction in LEE transcription (Deng et al., 2004).
This suggests that the SA compounds are unlikely to simply bind
to basal apparatus proteins, as this would not be consistent with
the transcriptional changes observed. Further evidence to explain
the MOA of the SA compounds comes from work investigat-
ing the type four secretion system (T4SS) of Brucella. T4SS have
a completely different protein structure compared to the T3SS
but are also important virulence factors for many Gram-negative
pathogens (Baron, 2006). Based on the knowledge that dimer-
ization of the assembly factor VirB8 is a prerequisite for VirB8
function, a bacterial two-hybrid assay was established (Smith
et al., 2012). This allowed several inhibitors of VirB8 dimerization
to be identified including B8I-2, a salicyidene acylhydrazide. Co-
crystals of B8I-2 and VirB8 were obtained, allowing the residues
critical for the inhibitory activity to be mapped. Interestingly,
when seven SAs that inhibited the T3SS were tested, all were
found to be inactive in the VirB8 interaction assay (Smith et al.,
2012). This raises the possibility that either the SA compounds
are rather promiscuous, and bind numerous proteins, or that
despite the absence of obvious protein sequence similarities, both
of the T3 and T4 secretion systems may be inhibited by a similar
mechanism.
In summary, it is easy to assume that because one has estab-
lished a screen for compounds that affect the expression of the
T3SS, the compounds are directly targeting the secretion system
itself. This assumption is dangerous and it is wise to determine
the global effects of any compound using either transcriptomic or
proteomic approaches before focusing on a subset of targets.
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DEFINING THE MECHANISM OF ACTION FOR AV
COMPOUNDS
From the outline above, it is clear that whilst it is relatively easy to
develop a robust screen and identify novel lead compounds, elu-
cidating their specific mode of action is much more problematic.
The first step toward unraveling the MOA of a novel compound is
to identify its cellular target or targets. There are several different
approaches that can be taken to investigate targets such as genetic
or biochemical screening and affinity chromatography. However,
when used in isolation these approaches will not always give a
clear answer and in our experience we have found that using a
combination of these approaches is most beneficial.
STRENGTHS AND LIMITATIONS OF APPROACHES TO
TARGET IDENTIFICATION
Most groups performing screening projects have a background
in bacteriology and therefore adopt classical genetics approaches
to try and understand MOA. For traditional antibiotics, simple
screens are often employed to identify mutants that are resistant
to the effects of the agent. Exposure of a large bacterial popu-
lation to a high dose of the antibiotic will often yield “escape
mutants” that are resistant to the compound (Bergstrom and
Feldgarden, 2008). Alternatively, saturated transposon mutagen-
esis can be employed in which a bank of mutants is created and
then screened for escape mutants. Genome sequencing is now
routine and affordable such that mutants can be readily analyzed
and the mutation identified. Ideally, the transposon would be in
a gene encoding the target, directly revealing the likely MOA.
However, resistant mutants can be more obscure, for example in
a porin or membrane transporter that results in a lower intra-
cellular concentration of the antibiotic (Fernández and Hancock,
2012). For AV compounds, an inherent limitation is often that the
screening of mutants is far more time-consuming than for bacte-
ricidal antibiotics. By their very design, AV agents do not affect
bacterial growth or survival so simply “plating out” a large pop-
ulation on a high concentration is not likely to produce resistant
mutants that will inform the MOA.
We have utilized two different approaches to identify escape
mutants. Firstly, generation of a transposon insertion library in
which each mutant is screened for expression of the T3SS and
secondly by screening “wild-type” isolates with a view to find-
ing variants that are less sensitive to the AV compound. In the
former, the process has proved to be time-consuming and is abso-
lutely dependent on the quality of the screen, in our case a GFP
transcriptional-reporter assay that can be run in 96-well plate for-
mat. Given that the EHEC genome carries approximately 5500
genes, there is no overcoming the large volume of work involved
in screening thousands of mutants. Moreover, for each mutant
that exhibits insensitivity to an AV compound, further screens
must be undertaken to verify that growth is unaffected. One
inherent limitation of such a screen is that, if the protein tar-
get were directly involved in the T3SS itself (such as a structural
protein), then insertion of a transposon into corresponding gene
would inhibit T3SS function entirely. Overall, the simplicity of
the approach needs to be balanced against the time needed to be
invested and should only be adopted if the screen is extremely
robust.
Our second approach has been to screen a bank of clini-
cal isolates. Selection of 18 clinical E. coli O157 isolates with a
diverse range of phage types revealed a strain that was completely
insensitive to the SA compounds. Next generation sequencing
provided rapid and accurate identification of genetic differences
when compared to that of reference strains. The success of this
approach is largely dependent on having access to a diverse strain
collection, as clonal isolates are likely to display little phenotypic
variation. However, greater diversity results in more genetic dif-
ferences. In our insensitive mutant there were over 1300 single
nucleotide polymorphisms (Wang et al., 2011). These data were a
useful comparator to other target identification approaches but,
in isolation, would not be sufficient to inform of a specific target
with confidence.
As discussed above, transcriptomic profiling, historically using
microarrays and more recently RNA-seq, is a powerful and unbi-
ased method to reveal insights into the global effects of any
compound. Although transcriptomic profiling reveals no direct
data as to the likely target protein or underlying mechanism it
does provide valuable data. In particular, it provides a clear indi-
cation as to the specificity of the compound: does it affect a
single operon, a network of genes or a substantial proportion
of the genome? As already described, for the SA compounds it
was clear that several operons, not just the LEE, were affected.
These data suggested that numerous target proteins were bound
or that the compounds interfered with core aspects of bacterial
physiology.
Alternatives to transcriptomic studies are the well-established
methods of proteomics and the relatively recent addition,
metabolomics. Using two-dimensional difference gel elec-
trophoresis (2D-DIGE) provides a sensitive and robust approach
to detecting changes in protein expression (Kondo andHirohashi,
2006). The most clear advantage being that it is possible to detect
possible post-transcriptional effects caused by any compound.
The major limitation is that only a proportion of the proteome
can be resolved on a single gel.
Metabolomics is widely used in the pharmaceutical industry
to test the effects of drugs on host-cell processes. For exam-
ple, metabolomic studies have demonstrated that D-cycloserine,
a second-line treatment for Mycobacterium tuberculosis, is
rather non-specific and causes inhibition of numerous enzymes
(Halouska et al., 2007), a result that might explain some of
the less-desirable side effects. However, metabolomics has barely
been applied to AV development. Targeted metabolomics follows
changes to a specific metabolite based on some prior informa-
tion, so it is unlikely to be used at an early stage or to reveal
information regarding a possible MOA. However, untargeted
metabolomics is discovery based and aims to monitor the entirety
of the metabolome in order to identify the affected metabo-
lites and pathways. It is feasible that metabolomics might reveal
discrete changes in pathways providing insights into the global
effects of an AV compound but it is likely to be employed at a
later stage to investigate potential toxicity issues when MOA has
been established.
Affinity chromatography is a powerful technique that enables
identification of compound binding partners from whole-cell
lysates. An overview of the basic steps is provided in Figure 1.
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FIGURE 1 | Overview of the affinity pull-down assay to determine the
binding proteins of the salicylidene acylhydrazides. (1) The hit compound
was identified from reporter assays screening for decreased T3SS
expression. (2) The hit compound was attached to an Affigel support. (3) The
Affigel labeled compound was mixed with cell lysate, allowing the putative
targets to bind. (4) Non-specifically bound proteins were removed by
washing and specifically bound proteins were eluted with high
concentrations of the free compound. (5) Eluted proteins were resolved by
SDS-PAGE and protein bands visualized by Colloidal Blue Stain and excised.
(6) Protein bands were identified by mass-spectrometry.
A successful pull-down first requires that the compound can be
attached to an immobile matrix without disrupting the activity
of the compound. This is not without complications as not all
of the chemical groups on the compound may be suitable for
attaching a linker to immobilize the compound. Therefore, it is
often valuable to conduct a structure-activity relationship (SAR)
where different chemical variants are screened against whole cells
in order to identify the regions of the molecule associated with
the desired phenotype. In the case of the SA compounds it was
found that the active groups of the compounds were located
on the right hand phenol group (Table 1) (Wang et al., 2011).
This knowledge allowed the design and synthesis of ME0055-Aff,
an Affigel labeled derivate of the SA inhibitor. Using the Affigel
labeled derivative an affinity pull-down assay of E. coli O157:H7
cell lystates identified 19 putative protein binding targets (Wang
et al., 2011). A combination of phenotypic analyses and biophys-
ical studies on purified proteins were used to critically assess the
contribution of these putative targets to the phenotype associated
with SA addition.
TARGET VALIDATION
The identification of putative target proteins is a great step for-
ward in understanding the MOA of a compound. However,
it is important to confirm any interaction and, more impor-
tantly, that the target is associated with the expected phenotype.
Our affinity chromatography experiments revealed multiple tar-
gets for the SA compounds (Wang et al., 2011). These were
likely a mix of genuine targets, false positives but also proteins
bound by the compound that did not contribute to the over-
all phenotype. To test this, we employed a variety of different
biophysical methods. These included chemical shift nuclear mag-
netic resonance (NMR), X-ray crystallography, and analytical
ultracentrifugation. Further approaches including surface plas-
mon resonance (SPR) and isothermal titration calorimetry (ITC)
would also be applicable but the low solubility of the SA com-
pounds in biologically relevant solutions made these problematic.
Chemical shift NMR allowed us to demonstrate that one tar-
get protein, a thiol peroxidase called Tpx was indeed a target of
the SA compounds. A discrete binding site at the dimer inter-
face was mapped and input from collaborators helped build a
model of the SA compounds bound to the oxidized form of Tpx
(Gabrielsen et al., 2012), validating the affinity chromatography
result. The finding that the SA compound bound at the dimer
interface is consistent with the aforementioned work in Brucella,
which showed a different SA compound inhibited dimerization
of VirB8 (Smith et al., 2012). However, deletion of the gene
encoding Tpx did not cause a dramatic effect on the expres-
sion of the T3SS. Some regulatory changes were seen, but not
the stark reduction in expression one might expect if the tar-
get protein was central to the phenotype. Our conclusion from
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this work was that inhibition of T3SS activity is due to a poly-
pharmacological effect on proteins involved in metabolism and
that there was no single clear target that we could attribute to
the phenotype. This highlights the importance of generating dele-
tion mutants for all putative targets at the earliest opportunity.
Indeed, following this approach we systematically deleted more
of the genes encoding putative target proteins including AdhE,
a bi-functional acetaldehyde-CoA dehydrogenase and alcohol
dehydrogenase involved in central metabolism. Deletion of the
gene encoding AdhE in EHEC caused a marked reduction in T3S
and an elevation of flagella production (Beckham et al., 2014),
both of which are phenotypes seen when the SA compounds
are added to EHEC. However, there were some clear regulatory
disparities when comparing the deletion of the gene encoding
AdhE and when the SA compounds are added. Specifically, dele-
tion of AdhE caused a post-transcriptional regulation of the LEE,
whereas addition of the SA compound showed transcriptional
repression. This difference might be attributed to a number of
factors. The generation of the defined deletion results in no
AdhE protein being produced. In comparison, if the SA com-
pounds affect AdhE activity, they are unlikely to completely block
both enzymatic functions. The prediction is that the metabolic
flux through the pathways associated with AdhE will be dif-
ferent in the two cases, the deletion compared with enzymatic
inhibition. However, by systematically analyzing each putative
target of the SA compounds, we have found a metabolic enzyme
that is clearly linked to virulence gene expression. Our working
model, in agreement with other studies (Martinez-Argudo et al.,
2013) suggests that the SA compounds bind several bacterial pro-
teins and affect virulence by disrupting several core metabolic
proteins.
CONCLUSIONS
The urgent need for need anti-infective agents is one of the most
pressing challenges facing the scientific community. AV agents
provide one route to new classes of drugs that are targeted to spe-
cific pathogens. The availability of small compound and natural
product libraries makes screening for leads relatively simple but
the largest challenge remains elucidating the precise MOA. An
integrated approach using both classical genetics and biochemical
methodologies is most likely to reveal this valuable information
and allow researchers to make the jump toward structure based
drug design and ultimately, clinically-relevant drugs.
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